Daniela Brunner, PhD, is the Chief Technology and Innovation Officer of PsychoGenics Inc., a preclinical CRO with the mission to provide the best disease models and preclinical capabilities to help companies discover the next breakthroughs for CNS and orphan disorders. Dr. Brunner received her Ph.D. at Cambridge University (U.K.) and postdoctoral training at Columbia University (USA). She joined PsychoGenics in 1999 where she developed preclinical tests for cognition, neurodegeneration, autism, and others. She conceived the SmartCube® system and worked in the development of all PsychoGenics’ AI technologies. She is in charge of all data science and services, including AI-based projects for generative de novo design of small CNS molecules and repurposing of drugs for rare disorders using phenotypic EEG and behavioral data. In the recent past she also worked in digital health, having founded Early Signal Foundation and ScienceForward LLC, organizations focused on digital technologies for human health. She has worked closely with many nonprofits working in rare disorders, including the Tuberous Sclerosis Alliance, Children’s Tumor Foundation, Cure VCP, and International Rett Syndrome Foundation. She enjoys photography and painting, and practices the old discipline of Kobudo.
